As of Nov 19, 2026, 2 of 2 active firms rate SRTS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SRTS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.13 – $-0.08 · 2 analysts · -34% YoY
Next period, 2 analysts expect Sensus Healthcare Inc to earn $-0.10 a share (range $-0.13 – $-0.08), versus $-0.16 a year earlier. Full-year consensus is $-0.81, growing to $-0.27 the year after.
REVENUE · NEXT QUARTER
$5.1M
Range $4.0M – $6.6M · 2 analysts · +50% YoY
Revenue is expected to reach $5.1M (range $4.0M – $6.6M), +50.3% year-over-year. Full-year consensus is $18.6M, rising to $27.2M next year.
Top analysts covering Sensus Healthcare Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SRTS.
#1
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$8.00+250.1% to target
Overall win rate
34%
+ Follow
#2
JW
Jason Wittes
Roth MKM · Rank #382
Buy
$10.00+337.6% to target
Overall win rate
40%
+ Follow
#3
Anthony Vendetti
Maxim Group · Rank #456
Buy
$6.00+162.6% to target
Overall win rate
28%
+ Follow
#4
BH
Ben Haynor
Lake Street
Buy
$4.00+75.1% to target
Coverage
—
+ Follow
#5
SH
Scott Henry
Alliance Global Partners
Buy
$5.50+140.7% to target
Coverage
—
+ Follow
SRTS stock forecast FAQ
What is SRTS's average 12-month price target?+
The 2 active firms with a live target average $5.00 for Sensus Healthcare Inc over the next 12 months, ranging from a $6.00 high to a $4.00 low, as of Nov 19, 2026.
Is SRTS stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SRTS?+
The Street-high target is $6.00 (Maxim Group), and the Street-low is $4.00 (Lake Street). The average of all 2 active-firm targets is $5.00.
How many active Wall Street firms cover SRTS?+
2 active firms have a recognized rating on Sensus Healthcare Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SRTS?+
Among analysts who currently cover SRTS, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $8.00 target.
What is Sensus Healthcare Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.13 – $-0.08) across 2 analysts. Full-year EPS is projected at $-0.81, rising to $-0.27 the following year.
How much revenue is Sensus Healthcare Inc expected to report next quarter?+
Consensus revenue is $5.1M (range $4.0M – $6.6M). Full-year revenue is projected at $18.6M, growing to $27.2M next year.
Have analysts been upgrading or downgrading SRTS lately?+
As of Nov 19, 2026, 2 of 2 active firms rate SRTS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SRTS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.